Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda By Sophie Beauvais | 04 Sep, 2008

Summary Points:

* The World Health Organization calls for massive scale-up of programmatic management of drug-resistant tuberculosis in resource-limited settings.

* Several technical and operational barriers impede the achievement of this scale-up.

* A research agenda, developed by the Stop TB Partnership, identifies the most important barriers and prioritizes the research questions to be addressed in order to overcome these barriers.

* Research priorities include: new and improved tools for drug resistance testing; clinical trials of simplified and shorter second-line treatment regimens; new and improved strategies for diagnosis of drug-resistant tuberculosis, treatment adherence, and infection control; understanding of the geographic variations in occurrence of drug resistance; and clinical trials of prophylactic treatment of contacts of patients with drug-resistant tuberculosis.

Attached resource:
  • Scaling Up Programmatic Management of Drug-Resistant Tuberculosis: A Prioritized Research Agenda (external URL)

    Link leads to: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0050150&ct=1

    Summary: Summary Points:

    * The World Health Organization calls for massive scale-up of programmatic management of drug-resistant tuberculosis in resource-limited settings.

    * Several technical and operational barriers impede the achievement of this scale-up.

    * A research agenda, developed by the Stop TB Partnership, identifies the most important barriers and prioritizes the research questions to be addressed in order to overcome these barriers.

    * Research priorities include: new and improved tools for drug resistance testing; clinical trials of simplified and shorter second-line treatment regimens; new and improved strategies for diagnosis of drug-resistant tuberculosis, treatment adherence, and infection control; understanding of the geographic variations in occurrence of drug resistance; and clinical trials of prophylactic treatment of contacts of patients with drug-resistant tuberculosis.

    Source: PLoS Medicine

    Publication Date: July 8, 2008

    Language: English

    Keywords: Publications & Research